ICER: Antibodies For MS – Including TG’s – Need Big Price Cut For Cost-Effectiveness

The pricing watchdog said it found “insufficient evidence” to differentiate the benefit of TG’s ublituximab from other antibodies already on the market for multiple sclerosis.